• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen is pleased to invite you to an upcoming webinar on November 20, 2025, at 15:00 GMT | 16:00 CET.

Nov 20, 2025 | 2025, Events, Investors

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link in the description or contact usat IR@philogen.com for further details.

The Board of Directors approves the financial position for the third quarter of 2025

Nov 11, 2025 | 2025, Investors, Press Releases

more details

Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa al terzo trimestre 2025

Nov 11, 2025 | 2025, Investors, Press Releases

more details

Philogen is pleased to invite you to an upcoming webinar on September 26, 2025, at 14:00 GMT | 15:00 CET.

Sep 26, 2025 | 2025, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link or contact us at IR@philogen.com for further details.

Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2025 (Price sensitive)

Sep 23, 2025 | 2025, Investors, Press Releases

more details

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2025 (Price sensitive) – Courtesy English Translation

Sep 23, 2025 | 2025, Investors, Press Releases

more details
« Older Entries

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philogen is pleased to invite you to an upcoming webinar on November 20, 2025, at 15:00 GMT | 16:00 CET.
  • The Board of Directors approves the financial position for the third quarter of 2025
  • Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa al terzo trimestre 2025
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it